ClinicalTrials.Veeva

Menu
B

BRCR Medical Center | Plantation, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Docetaxel
Lenalidomide
Ontamalimab
Cyclophosphamide
MT-5111
HBI-2376
ACE-536
Platinum
Decitabine
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 37 total trials

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recom...

Enrolling
Solid Tumor
Cancer of Pancreas
Drug: HBI-2438

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and r...

Enrolling
Solid Tumor
Cancer of Colon
Drug: HBI-2376

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced sol...

Enrolling
HER2-positive Advanced Solid Tumor
Drug: Itraconazole
Drug: Ritonavir

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Enrolling
Polycythemia Vera
Drug: Placebo
Drug: Rusfertide

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: rituximab
Drug: placebo

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling
Myelofibrosis
Drug: Imetelstat
Drug: Best Available Therapy (BAT)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

The participants of this study would have relapsed/refractory follicular lymphoma.Follicular lymphoma is a type of blood cancer. It is referred to as...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Follicular Lymphoma
Combination Product: Rituximab
Drug: Placebo oral tablet

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Enrolling
Anemia
Myelofibrosis
Other: Placebo
Drug: ACE-536

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, c...

Active, not recruiting
Nonsmall Cell Lung Cancer
NSCLC
Drug: Immune checkpoint inhibitors or docetaxel
Device: NovoTTF-200T

Brief Summary:The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFie...

Active, not recruiting
Pancreas Adenocarcinoma
Drug: Gemcitabine
Drug: nab paclitaxel

The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answe...

Enrolling
HER2 Mutant Non-small Cell Lung Cancer
HER2 Amplification
Drug: ELVN-002
Drug: Trastuzumab emtansine

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants...

Enrolling
HER2 Positive Solid Tumors
HER2-positive Gastric Cancer
Drug: paclitaxel
Drug: Leucovorin

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with O...

Active, not recruiting
Endometrial Cancer
Solid Tumor
Biological: T3011

This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in...

Active, not recruiting
Non-Small Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Drug: efineptakin alfa
Drug: Atezolizumab

The purpose of this study is to compare the effect of Eflapegrastim on duration of neutropenia in patients with early-stage breast cancer when admini...

Active, not recruiting
Breast Cancer
Neutropenia
Biological: Eflapegrastim
Drug: Cyclophosphamide

Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic respons...

Active, not recruiting
Myelodysplastic Syndromes
Drug: ASTX727 LD
Drug: ASTX727 SD

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: Cetuximab
Drug: Afatinib

Trial sponsors

Pfizer logo
E
G
H
Mirati Therapeutics logo
Molecular Templates logo
NovoCure logo
Shire logo
Spectrum Pharmaceuticals logo
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems